Industry News
Biotechnology Industry News
Rivus throws down mid-stage liver fat data on quest to climb NASH mountain
Rivus throws down mid-stage liver fat data on quest to climb NASH mountain aarmstrong Wed, 02/09/2022 - 09:36
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic ntaylor Wed, 02/09/2022 - 08:14
GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pact
GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pact ntaylor Wed, 02/09/2022 - 06:17
GSK kills one of Barron’s early darlings, axing 2 synthetic lethal programs and Epizyme pact
GSK kills one of Barron's early darlings, axing 2 synthetic lethal programs and Epizyme pact ntaylor Wed, 02/09/2022 - 06:17
Chutes & Ladders—Editas fires chief medical officer without explanation
Chutes & Ladders—Editas fires chief medical officer without explanation admin Tue, 02/08/2022 - 17:11
Biotech IPOs in the current market environment? Experts say it’s ‘a bit silly, if not suicidal’
Biotech IPOs in the current market environment? Experts say it's 'a bit silly, if not suicidal' klahucik Tue, 02/08/2022 - 16:47
With $1.7T in the coffers, biopharma M&A expected to be ‘a different animal’ in 2022
With $1.7T in the coffers, biopharma M&A expected to be 'a different animal' in 2022 klahucik Tue, 02/08/2022 - 14:11
Axsome’s migraine drug finally slated for FDA inspection but investors really want to know about stalled depression therapy
Axsome’s migraine drug finally slated for FDA inspection but investors really want to know about stalled depression therapy mbayer Tue, 02/08/2022 - 11:59
Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy
Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy mbayer Tue, 02/08/2022 - 11:59
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X ntaylor Tue, 02/08/2022 - 09:01
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling to leave ACTIV-3 future in doubt
Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling to leave ACTIV-3 future in doubt ntaylor Tue, 02/08/2022 - 08:06
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling in further blow to ACTIV-3
Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling in further blow to ACTIV-3 ntaylor Tue, 02/08/2022 - 08:06
Bristol Myers Squibb doles out $8M in new grants to improve health equity with cardiovascular, oncology focus
Bristol Myers Squibb doles out $8M in new grants to improve health equity with cardiovascular, oncology focus mbayer Mon, 02/07/2022 - 22:55
Congruence pulls in $50M series A to build a team of ‘drug hunters’ to go after rare disease targets
Congruence pulls in $50M series A to build a team of 'drug hunters' to go after rare disease targets ssorensen Mon, 02/07/2022 - 14:40
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patients
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patients klahucik Mon, 02/07/2022 - 10:04
Boundless Bio lures Berkley from Ionis to support clinical push
Boundless Bio lures Berkley from Ionis to support clinical push ntaylor Mon, 02/07/2022 - 09:01
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitor
CANbridge, targeting gaps in AstraZeneca's rare disease coverage, posts early-phase data on C5 inhibitor ntaylor Mon, 02/07/2022 - 08:02
Takeda joins Novartis and Merck in $45M funding for Koneksa Health
Takeda joins Novartis and Merck in $45M funding for Koneksa Health ssorensen Fri, 02/04/2022 - 13:13
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drug
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck's drug klahucik Fri, 02/04/2022 - 12:45
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal klahucik Fri, 02/04/2022 - 11:31